Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd6ad2ba308307112ce6de3052427f51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_244630447017dc0b8a917a82d7ad0036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ab26596c5f45df79d217920da474e6 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 |
filingDate |
2008-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ac02deccee8580c58fc9c0c6074dce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4771be0b0ca117b7879e765f04e0ab22 |
publicationDate |
2008-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2008137600-A1 |
titleOfInvention |
Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
abstract |
A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin El (PGEl). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin El (PGEl), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9341637-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9506938-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102843967-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8574828-B2 |
priorityDate |
2007-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |